Glioma News and Research

RSS

Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).

New perspectives on targeting BRAF alterations in cancer

A new research perspective was published in Oncotarget's Volume 15 on July 16, 2024, entitled, "Targeting the multifaceted BRAF in cancer: New directions."

12 Aug 2024

From discovery to approval: Vorasidenib approved by FDA for treatment of IDH-mutant gliomas

A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA).

7 Aug 2024

FDA approves vorasidenib for Grade 2 gliomas with IDH mutations

Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations.

6 Aug 2024

UCLA launches groundbreaking clinical trial for vaccine targeting aggressive pediatric brain cancer

In an effort to combat one of the most lethal forms of pediatric brain cancer, researchers at the UCLA Health Jonsson Comprehensive Cancer Center are launching a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine targeting H3 G34-mutant diffuse hemispheric glioma, a highly aggressive brain tumor that is typically found in adolescents and young adults.

5 Aug 2024

Kaempferol's promise in fighting triple-negative breast cancer

Review highlights kaempferol's potential in treating triple-negative breast cancer through various anticancer mechanisms and improving chemotherapeutic efficacy.

24 Jul 2024

Study highlights the role of RGS16 in glioma progression

Gang Li et al., at Department of Neurosurgery, Qilu Hospital, Shandong University, China, presented a comprehensive study on the role of regulator of G-protein signaling 16 (RGS16) in the progression of glioma, a highly aggressive central nervous system tumor.

17 Jul 2024

FDA expands orphan drug designation for Roswell Park's brain cancer immunotherapy

The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.

25 Jun 2024

Study sheds light on pediatric DIPG tumor mechanisms

Researchers at the University of Michigan Health Rogel Cancer Center are one step closer to understanding how pediatric DIPG tumors work.

13 Jun 2024

Curcumin nanoparticles show promise in treating neurodegenerative diseases

Review demonstrates curcumin's neuroprotective effects in neurodegenerative diseases, enhancing its potential through innovative nanoparticle formulations. This advancement could significantly improve treatments for diseases like Parkinson's, Alzheimer's, and Multiple Sclerosis.

6 Jun 2024

New surgical platform informs critical decision-making about tumor treatment within minutes

Brain cancer is difficult to treat when it starts growing, and a prevalent type, known as a glioma, has a poor five-year survival rate.

30 May 2024

Study identifies PI3K-beta as key target in overcoming chemotherapy resistance in glioblastoma

For many patients with a deadly type of brain cancer called glioblastoma, chemotherapy resistance is a big problem.

20 May 2024

Disabling survival pathways could be a promising strategy for brain tumor treatment

When you disable the brakes on a race car, it quickly crashes. Dr. Barak Rotblat wants to do something similar to brain cancer cells.

20 May 2024

Machine learning enhances early detection of glioma mutations

Machine learning (ML) methods can quickly and accurately diagnose mutations in gliomas – primary brain tumors.

20 May 2024

Study proposes a novel therapeutic avenue for tackling EHF-induced cholangiocarcinogenesis

This study is led by Dr. Yiming Luo (Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) and Professor. Huifang Liang (Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology).

14 May 2024

Combination immunotherapy treatment enhances immune response for people with malignant gliomas

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an aggressive type of brain tumor that is fast growing and difficult to treat.

9 May 2024

Unlocking glioblastoma's immune suppression mechanism

The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma - a serious and often fatal brain cancer - suppresses the immune system so that the tumor can grow unimpeded by the body's defenses.

3 May 2024

Epilepsy drug prevents brain tumor formation and growth in mouse models of NF1

A drug used to treat children with epilepsy prevents brain tumor formation and growth in two mouse models of neurofibromatosis type 1 (NF1), according to a study by researchers at Washington University School of Medicine in St. Louis.

15 Apr 2024

Study demonstrates the function and molecular mechanism of circHAS2 in gliomas

Announcing a new article publication for BIO Integration journal. Circular RNAs (circRNAs) regulate tumor development by interacting with microRNAs.

15 Apr 2024

Revolutionizing brain tumor treatment: the rise of AI in neuro-oncology

The current state of knowledge about the role of artificial intelligence (AI) in the diagnosis, treatment, and prognosis of brain tumors.

2 Apr 2024

Uncovering gender-specific genetic alterations in cancer

Recent research spearheaded by Chunmei Cui at the State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, China, casts a new light on the nuanced interplay between gender and cancer, uncovering significant sex-specific disparities in copy number alterations (CNA) across various cancer types.

29 Mar 2024

Glioma News and Research

Further Reading

New perspectives on targeting BRAF alterations in cancer

From discovery to approval: Vorasidenib approved by FDA for treatment of IDH-mutant gliomas

FDA approves vorasidenib for Grade 2 gliomas with IDH mutations

UCLA launches groundbreaking clinical trial for vaccine targeting aggressive pediatric brain cancer

Kaempferol's promise in fighting triple-negative breast cancer

Study highlights the role of RGS16 in glioma progression

FDA expands orphan drug designation for Roswell Park's brain cancer immunotherapy

Study sheds light on pediatric DIPG tumor mechanisms

Curcumin nanoparticles show promise in treating neurodegenerative diseases

New surgical platform informs critical decision-making about tumor treatment within minutes

Study identifies PI3K-beta as key target in overcoming chemotherapy resistance in glioblastoma

Disabling survival pathways could be a promising strategy for brain tumor treatment

Machine learning enhances early detection of glioma mutations

Study proposes a novel therapeutic avenue for tackling EHF-induced cholangiocarcinogenesis

Combination immunotherapy treatment enhances immune response for people with malignant gliomas

Unlocking glioblastoma's immune suppression mechanism

Epilepsy drug prevents brain tumor formation and growth in mouse models of NF1

Study demonstrates the function and molecular mechanism of circHAS2 in gliomas

Revolutionizing brain tumor treatment: the rise of AI in neuro-oncology

Uncovering gender-specific genetic alterations in cancer

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News